뒤로
Lexicon Pharmaceuticals Inc(LXRX) 가격
LXRX 주가 차트
LXRX 수입
Lexicon Pharmaceuticals Inc
$1.37
4.88%
$0.06
오늘 기준:Jan 21, 09:44:56 GMT-5
최신 수익 결과: Q3 '25
보고됨: 2025-11-06
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
LXRX의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Lexicon Pharmaceuticals Inc LXRX의 지난 분기 매출 실적은 어땠나요?
Lexicon Pharmaceuticals Inc의 매출 추정치는 얼마인가요?
Lexicon Pharmaceuticals Inc의 수익 품질 점수는 얼마인가요?
Lexicon Pharmaceuticals Inc는 언제 수익을 보고하나요?
Lexicon Pharmaceuticals Inc의 예상 수익은 얼마인가요?
Lexicon Pharmaceuticals Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$1.31
시가
$1.33
일일 범위
$1.33 - $1.39
52주 범위
$0.28 - $1.66
거래량
420.4K
평균 거래량
1.7M
EPS(TTM)
-0.19
배당수익률
--
시가총액
$499.3M
LXRX란 무엇인가요?
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company is headquartered in The Woodlands, Texas and currently employs 103 full-time employees. The company went IPO on 2000-04-07. The company is developing pilavapadin (LX9211), an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The company has completed three Phase II clinical trials evaluating the safety and tolerability of pilavapadin and its effects on diabetic peripheral neuropathic pain (DPNP) and neuropathic pain. The company is developing LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic disorders and is conducting preclinical development of LX9851 in preparation for filing an investigational new drug application. The company is commercializing INPEFA (sotagliflozin), an orally delivered small molecule drug, in the United States to reduce the risk of cardiovascular death, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus.